Subsequently, many specific PDE4 inhibitors acting in the nanomolar range were conceived as anti-inflammatory agents for asthma and COPD, as they reduced oxidative stress, TNF-α, and cytokine production. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.